- Home
- GFL vs MRNA Comparison
GFL vs MRNA Comparison
Compare GFL & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GFL
- MRNA
- Stock Information
- Founded
- GFL 2007
- MRNA 2010
- Country
- GFL Canada
- MRNA United States
- Employees
- GFL N/A
- MRNA N/A
- Industry
- GFL
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- GFL
- MRNA Health Care
- Exchange
- GFL Nasdaq
- MRNA Nasdaq
- Market Cap
- GFL 18.1B
- MRNA 16.0B
- IPO Year
- GFL 2020
- MRNA 2018
- Fundamental
- Price
- GFL $48.80
- MRNA $27.22
- Analyst Decision
- GFL Strong Buy
- MRNA Hold
- Analyst Count
- GFL 8
- MRNA 20
- Target Price
- GFL $51.25
- MRNA $54.47
- AVG Volume (30 Days)
- GFL 2.2M
- MRNA 9.7M
- Earning Date
- GFL 04-30-2025
- MRNA 05-01-2025
- Dividend Yield
- GFL 0.13%
- MRNA N/A
- EPS Growth
- GFL N/A
- MRNA N/A
- EPS
- GFL N/A
- MRNA N/A
- Revenue
- GFL $5,464,123,877.00
- MRNA $3,236,000,000.00
- Revenue This Year
- GFL N/A
- MRNA N/A
- Revenue Next Year
- GFL $6.28
- MRNA $22.07
- P/E Ratio
- GFL N/A
- MRNA N/A
- Revenue Growth
- GFL 4.61
- MRNA N/A
- 52 Week Low
- GFL $30.57
- MRNA $23.15
- 52 Week High
- GFL $49.45
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- GFL 55.16
- MRNA 47.01
- Support Level
- GFL $47.32
- MRNA $26.33
- Resistance Level
- GFL $48.83
- MRNA $27.88
- Average True Range (ATR)
- GFL 1.45
- MRNA 1.84
- MACD
- GFL 0.07
- MRNA 0.43
- Stochastic Oscillator
- GFL 86.97
- MRNA 86.05
About GFL GFL Environmental Inc. Subordinate voting shares no par value
GFL Environmental Inc is an environmental services company. Its offerings include non-hazardous solid waste management, infrastructure, soil remediation, and liquid waste management services. Its solid waste management business line, which generates the majority of the revenue, consists of the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste. Its Environmental Services business line includes liquid waste and soil remediation. The company's geographical segments are Canada and the United States. The company derives the majority of its revenue from the United States.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.